Episode 43: StĂ©phanie LĂ©garĂ© â First Systematic Review of Placebo Response in CLE Trials
Weâre joined by Dr. StĂ©phanie LĂ©garĂ©, Scientific Advisor, Indero, who has more than a decade of expertise in scientific medical communication, and translational and clinical research. She obtained her PhD in experimental medicine at McGill University, has taught biological sciences for several years, and has worked for eight years at Indero. StĂ©phanie is first author on […]
Understanding Complex Synergistic Drivers: Mitigating Placebo Response in Rheumatoid Arthritis Clinical Trials, Part 1 of 3
Novel therapeutic agents, like biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), have transformed the prognostic landscape for people living with rheumatoid arthritis (RA) in recent years. However, the future looks potentially a great deal less promising. Year after year, one randomized, double-blind, placebo-controlled trial after another, placebo response rates have […]
Placebo Response in Randomised Controlled Trials of Systemic Therapies for Cutaneous Lupus Erythematosus: A Systematic Review and Meta-Analysis
Authors: LĂ©garĂ©, S., Lin, S., Vahey, S., Ovalles-Bonilla, J. G., D’Angelo, P., Jankicevic, J., & Bissonnette, R. Read more on pubmed
Nine Strategies to Address High Placebo-Arm Response in Systemic Lupus Erythematosus (SLE) Clinical Trials
In systemic lupus erythematosus (SLE) trials, the control arm is never an untreated arm. Patients randomized to placebo receive an established, potent background regimen: glucocorticoids, hydroxychloroquine, and immunosuppressants such as mycophenolate or azathioprine. These are not inert comparators. They are active medicines that meaningfully reduce disease activity on their own, and those improvements register as […]
Eureka! Insights from EULAR 2026, Rheumatology’s Euro-Bonanza
PMR and PsA and SSc… Oh my! So much innovation discussed earlier this month at the mammoth rheumatology scientific congress of EULAR – the European Alliance of Associations for Rheumatology, in London, England. During days of wet and dark skies, EULAR 2026 was lit up with bright insights on rheumatology science and the business of conducting rheumatology clinical trials.  Indero’s rheumatology experts were among the almost 15,000 people at the congress. At an investigator advisory board the first day […]
Episode 41: Ekaterina Radchenko â Eurekas from EULAR 2026: Rheumatology’s Euro-bonanza!
One of the world’s largest scientific conferences in rheumatology, EULAR 2026, happened this month, and among the almost 15,000 attendees this year was Ekaterina Radchenko, Senior Project Manager in Indero. Located in Germany, Ekaterina has spent 18 years working in the clinical research industry on the CRO side. Indero sat down at EULAR 2026 with […]
Rheumatology Trial Readiness Checklist
Systemic Sclerosis Case Study
Click here for a PDF version of this case study Indero helped optimize recruitment and logistics for this systemic sclerosis (SSc) study. Outcomes Effective study design and patient management leading to 96% patient retention Patient recruitment was completed on time without any advertisement despite longer timelines associated with academic sites and the institutional burden […]
Top Rheumatology Conferences to Attend
The rheumatology clinical research industry thrives on innovation, collaboration, and scientific advancements. Conferences are essential in nurturing these aspects, offering platforms for experts to exchange knowledge, discuss breakthroughs, and join forces to achieve the ultimate common goal: discovering new therapies and improving patientsâ lives. Here, we highlight the top rheumatology conferences that make significant contributions […]
Key Sessions to Attend at ACR ConvergenceâŻ2025
The American College of Rheumatology (ACR) ConvergenceâŻ2025, the worldâs premier rheumatology experience, will take place October 24â29 in Chicago, Illinois. This yearâs program offers a unique opportunity for clinical trial professionals and CRO teams to gain insights into protocol design, operational execution, and regulatory strategy in autoimmune research. Below is a curated list of sessions […]
